Advertisement

International Journal of Hematology

, Volume 110, Issue 2, pp 228–236 | Cite as

Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma

  • Takashi Yoshida
  • Masaki RiEmail author
  • Haruna Fujinami
  • Yoshiko Oshima
  • Takuto Tachita
  • Yoshiaki Marumo
  • Hirokazu Sasaki
  • Shiori Kinoshita
  • Haruhito Totani
  • Tomoko Narita
  • Ayako Masaki
  • Asahi Ito
  • Shigeru Kusumoto
  • Takashi Ishida
  • Hirokazu Komatsu
  • Shinsuke Iida
Original Article
  • 126 Downloads

Abstract

Lenalidomide is an effective therapeutic agent for multiple myeloma (MM). However, its efficacy in the context of chromosomal abnormalities (CA) is poorly understood. We retrospectively analyzed 83 patients with relapsed/refractory (RR) MM, who received lenalidomide plus low-dose dexamethasone (Ld), in the context of CA. The median age and number of prior therapies were 69 and 2, respectively. Three, 11, 45, and 19 patients achieved complete response, very good partial response, partial response, and stable disease, respectively. Median progression-free survival (PFS) and overall survival (OS) were 11.1 and 38.8 months, respectively. Seventy-two patients were evaluated for frequently observed translocations; median PFS was 24.4 months in 20 patients with t(11;14), 13.0 months in 16 patients with t(4;14), and 3.7 months in seven patients with t(14;16). G-banded karyotype analysis detected 11 hypodiploid patients, who had shorter PFS and OS (2.5 and 6.2 months, respectively) compared to others (13.0 and 43.7 months, respectively). Hypodiploid patients showed poor clinical outcome, whereas patients with t(11;14) showed favorable outcome. In summary, the present study presents the clinical impact of chromosomal abnormalities on the outcome of Ld therapy, and contributes to understanding the appropriate choice of lenalidomide-based therapy to achieve effective treatment of RR MM.

Keywords

Multiple myeloma Chromosomal abnormalities Lenalidomide 

Notes

Acknowledgements

This work was partly supported by a Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (16K07179 & 16K09855), the National Cancer Center Research and Development Fund (26-A-4), and the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development, AMED (15ck0106077h0002).

Compliance with ethical standards

Conflict of interest

MR received research funding from Celgene Co., Ltd. SI received research funding and declares Honoraria from Janssen Pharmaceutical K.K., and Celgene Co., Ltd. SI also received research funding from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Takeda Yakuhin Co., Ltd., and Ono Pharmaceutical Co., Ltd.

Supplementary material

12185_2019_2669_MOESM1_ESM.pptx (90 kb)
Supplementary material 1 (PPTX 89 kb)
12185_2019_2669_MOESM2_ESM.doc (34 kb)
Supplementary material 2 (DOC 33 kb)
12185_2019_2669_MOESM3_ESM.doc (32 kb)
Supplementary material 3 (DOC 31 kb)

References

  1. 1.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.CrossRefGoogle Scholar
  2. 2.
    Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.CrossRefGoogle Scholar
  3. 3.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.CrossRefGoogle Scholar
  4. 4.
    Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–52.CrossRefGoogle Scholar
  5. 5.
    Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol. 2013;31:2806–9.CrossRefGoogle Scholar
  6. 6.
    Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013;97:313–23.CrossRefGoogle Scholar
  7. 7.
    Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117:4696–700.CrossRefGoogle Scholar
  8. 8.
    Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427–36.CrossRefGoogle Scholar
  9. 9.
    Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041–7.CrossRefGoogle Scholar
  10. 10.
    Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Groupe Francais de Cytogenetique H Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–38.CrossRefGoogle Scholar
  11. 11.
    Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–75.CrossRefGoogle Scholar
  12. 12.
    Klein U, Jauch A, Hielscher T, Hillengass J, Raab MS, Seckinger A, et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011;117:2136–44.CrossRefGoogle Scholar
  13. 13.
    Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204:3–12.CrossRefGoogle Scholar
  14. 14.
    Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia. 2010;24:623–8.CrossRefGoogle Scholar
  15. 15.
    Chang H, Jiang A, Qi C, Trieu Y, Chen C, Reece D. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma. 2010;51:2084–91.CrossRefGoogle Scholar
  16. 16.
    Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24:1769–78.CrossRefGoogle Scholar
  17. 17.
    Kim K, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, et al. Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. Ann Hematol. 2014;93:113–21.CrossRefGoogle Scholar
  18. 18.
    Kuroda J, Kobayashi T, Taniwaki M. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. Expert Rev Anticancer Ther. 2015;15:787–804.CrossRefGoogle Scholar
  19. 19.
    Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522–5.CrossRefGoogle Scholar
  20. 20.
    Narita T, Inagaki A, Kobayashi T, Kuroda Y, Fukushima T, Nezu M, et al. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015;5:e285.CrossRefGoogle Scholar
  21. 21.
    Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, et al. Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study. Cancer Sci. 2016;107:653–8.CrossRefGoogle Scholar
  22. 22.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefGoogle Scholar
  23. 23.
    Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, et al. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res. 2013;37:1648–55.CrossRefGoogle Scholar
  24. 24.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefGoogle Scholar
  25. 25.
    Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27:711–7.CrossRefGoogle Scholar
  26. 26.
    Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia. 2015;29:2119–25.CrossRefGoogle Scholar
  27. 27.
    Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, et al. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. Int J Hematol. 2015;101:37–45.CrossRefGoogle Scholar
  28. 28.
    Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–5.CrossRefGoogle Scholar
  29. 29.
    Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, et al. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. Blood Cancer J. 2019;9:13.CrossRefGoogle Scholar
  30. 30.
    Zambello R, Bonaldi L, Berno T, Martines A, Sechettin E, De March E, et al. Cytogenetic impact on lenalidomide treatment in relapsed/refractory multiple myeloma: a real-life evaluation. Clin Lymphoma Myeloma Leuk. 2015;15:592–8.CrossRefGoogle Scholar
  31. 31.
    Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, et al. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013;98:1586–92.CrossRefGoogle Scholar
  32. 32.
    Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4:e239.CrossRefGoogle Scholar
  33. 33.
    Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522–5.CrossRefGoogle Scholar
  34. 34.
    Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364–7.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Takashi Yoshida
    • 1
  • Masaki Ri
    • 1
    Email author
  • Haruna Fujinami
    • 1
  • Yoshiko Oshima
    • 1
  • Takuto Tachita
    • 1
    • 2
  • Yoshiaki Marumo
    • 1
  • Hirokazu Sasaki
    • 1
  • Shiori Kinoshita
    • 1
  • Haruhito Totani
    • 1
  • Tomoko Narita
    • 1
  • Ayako Masaki
    • 1
  • Asahi Ito
    • 1
  • Shigeru Kusumoto
    • 1
  • Takashi Ishida
    • 1
  • Hirokazu Komatsu
    • 1
  • Shinsuke Iida
    • 1
  1. 1.Department of Hematology and OncologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Gastroenterology and HematologyHirosaki University Graduate School of MedicineHirosakiJapan

Personalised recommendations